Cutanix distribution
This article was originally published in The Rose Sheet
Executive Summary
Copper peptide technology manufacturer ProCyte will market Cutanix Dramatic Relief product line to 3,000 physicians under exclusive distribution agreement, Redmond, Wash. firm announces. Two-year deal covers distribution rights for the medical and spa markets for all current and future Cutanix products formulated with Quadrinone. Patent-pending technology reduces inflammation associated with conditions such as rosacea and eczema, according to the company. Introduced in June 2002, Cutanix Dramatic Relief products include lotions for dry to normal skin, sensitive facial skin and oily and acne-prone skin, which retail for $45. Cutanix will launch Dramatic Relief body lotion, extra strength lotion and intensified eye serum in October...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.